Ryan Reed to Compete for GMS Racing at Darlington Raceway

Ryan Reed will pilot the No. 24 Tandem Diabetes Care Chevrolet Silverado at Darlington Raceway this Friday reports GMS Racing officials.

Ryan Reed said, “I’m so excited and I can’t thank Chevy and everyone at GMS, Mike (Beam) and Maury (Gallagher), enough for the opportunity.” He added, “It is awesome to see a new partner come into the sport with Tandem Diabetes Care. I use their t:slim X2 insulin pump to help manage my type 1 diabetes and their advanced Control-IQ technology has improved my health overall. It’s incredible to be able to represent them on the track and have my daily life changed by their product.”

A new partner in NASCAR, Tandem Diabetes Care is dedicated to making the lives of people with diabetes better through relentless innovation and revolutionary customer experience.

“We are thrilled that Ryan (Reed) is experiencing the benefits of the t:slim X2 pump with Control-IQ technology, and couldn’t be more excited to support him in following his passion,” said John Sheridan, President and CEO, Tandem Diabetes Care. “We’re constantly hearing from customers about how our technology is changing lives and we believe that Ryan getting behind the wheel this weekend is yet another example of these positive outcomes.”

“We’re very grateful to have talented drivers like Ryan (Reed) to be able to step up and compete for us,” said Mike Beam, President of GMS Racing. “We’re thankful for him and his partner Tandem Diabetes Care for coming on board with us for Darlington.”

The No. 24 Tandem Diabetes Care Chevrolet Silverado will make it’s on-track debut in the LIftKits4Less.com 200 at Darlington Raceway on Friday, May 7. The race will be broadcast live on FS1 and MRN.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.